Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levofloxacin→

Levofloxacin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
100986-85-4
Molecular formula
C18H20FN3O4
Molecular weight
361.4 g/mol
Drug class
Fluoroquinolone AntibacterialAntibiotic
Mechanism of action
DNA Gyrase Inhibitors
Indications / reported uses
  • Bronchitis
  • Chlamydia Infections
  • Escherichia coli Infections
  • Haemophilus Infections
  • Klebsiella Infections
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levofloxacin Environmental Risk Assessment (ERA) (the Levofloxacin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.